Pubblicazioni

ImmuneOncology-tyrosine kinase inhibitors combination, sometimes less is more

2021 - INTERNATIONAL IMMUNOPHARMACOLOGY

Stellato, M.; Santini, D.

Bevacizumab as first-line treatment in HER2-negative advanced breast cancer. Pros and cons

2016 - TUMORI

Sini, Valentina; Cassano, Alessandra; Corsi, Domenico; De Laurentiis, Michele; Gamucci, Teresa; Mauri, Mariella; Naso, Giuseppe; Roselli, Mario; Ruggeri, Enzo Maria; Tonini, Giuseppe; Vici, Patrizia; Zampa, Germano; Marchetti, Paolo

Current status of immunotherapy for non-small-cell lung cancer

2016 - TUMORI

Imbimbo, Martina; Lo Russo, Giuseppe; Blackhall, Fiona